Founded in 2019, PTM Therapeutics is a San Francisco-based, pre-clinical stage startup that strives to “develop therapeutics for the betterment
Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial
Vaxcyte is set to raise $500 million via a stock sale to fund its work on a pneumococcal vaccine it
CAMBRIDGE, Mass., Sept. 20, 2022 /PRNewswire/ -- Octagon Therapeutics, a preclinical-stage biopharmaceutical company developing targeted medicines for autoimmune disease, today announced the
MENLO PARK, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments
SAN DIEGO--(BUSINESS WIRE)-- Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered,
Financing co-led by seasoned healthcare investors, CAM Capital and Polaris Partners SAN DIEGO--(BUSINESS WIRE)-- Primmune Therapeutics today announced the initial closing of
FOSTER CITY, Calif., June 16, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing